New York State Common Retirement Fund Has $7.71 Million Position in Revvity Inc. (NYSE:RVTY)

New York State Common Retirement Fund boosted its holdings in Revvity Inc. (NYSE:RVTY - Free Report) by 4.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,911 shares of the company's stock after purchasing an additional 3,300 shares during the period. New York State Common Retirement Fund owned about 0.06% of Revvity worth $7,714,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Optiver Holding B.V. bought a new position in shares of Revvity in the 4th quarter valued at about $33,000. Quarry LP boosted its holdings in shares of Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after buying an additional 95 shares during the period. Millstone Evans Group LLC bought a new stake in shares of Revvity during the 4th quarter worth about $38,000. Vermillion Wealth Management Inc. bought a new stake in shares of Revvity during the 4th quarter worth about $41,000. Finally, Continuum Advisory LLC boosted its holdings in shares of Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock worth $53,000 after buying an additional 133 shares during the period. Institutional investors own 86.65% of the company's stock.

Revvity Price Performance

Shares of Revvity stock traded down $2.36 during midday trading on Monday, hitting $90.90. 1,350,133 shares of the company traded hands, compared to its average volume of 979,709. The stock has a market cap of $10.71 billion, a price-to-earnings ratio of 38.68, a PEG ratio of 2.35 and a beta of 0.98. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.99 and a current ratio of 3.58. The firm's fifty day moving average price is $95.10 and its 200-day moving average price is $103.86. Revvity Inc. has a 12 month low of $87.70 and a 12 month high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. Revvity had a net margin of 10.35% and a return on equity of 7.73%. The firm had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. During the same period in the previous year, the firm posted $0.98 EPS. The company's revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date of this dividend is Friday, July 18th. Revvity's dividend payout ratio is currently 11.91%.

Analyst Ratings Changes

RVTY has been the subject of several analyst reports. Raymond James Financial reiterated an "outperform" rating and issued a $120.00 price objective (down previously from $145.00) on shares of Revvity in a research note on Tuesday, April 29th. Robert W. Baird dropped their price objective on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, April 29th. Wall Street Zen cut shares of Revvity from a "buy" rating to a "hold" rating in a research note on Friday. Evercore ISI dropped their price objective on shares of Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a research note on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $123.07.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.